-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KCrL7+Bu+XLgM/5HgpsbPN+KMBULsnvhRS/gNLonYoY9SCQ/XKfnaf9SHaK8k3ug
 sYUWsWZtazdsLIgYMzW2Jg==

<SEC-DOCUMENT>0001019687-10-003861.txt : 20101101
<SEC-HEADER>0001019687-10-003861.hdr.sgml : 20101101
<ACCEPTANCE-DATETIME>20101101133558
ACCESSION NUMBER:		0001019687-10-003861
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20101027
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101101
DATE AS OF CHANGE:		20101101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		101154238

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE #660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-102710.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<html>
<head>
    <title>aethlon_8k-102710.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<br>
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C. 20549</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CURRENT REPORT</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Report (Date of earliest event reported): October 27, 2010</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AETHLON MEDICAL, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact name of registrant as specified in its charter)</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(State or other jurisdiction</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">of incorporation)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">000-21846</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Commission File Number)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13-3632859</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(IRS Employer</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="29%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8910 University Center Lane, Suite 660</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">San Diego, California</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="23%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">92122</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s telephone number, including area code: (858) 459-7800</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former name or former address, if changed since last report.)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: white" align="left" noshade size="1" width="100%">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ITEM 5.02</font></div>
</td>
<td align="left" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Appointment of Officer</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Effective October 27, 2010, Mr. Rod Kenley was appointed by the Board of Directors of Aethlon Medical, Inc. (the &#8220;Company&#8221;) to serve as the Company's President.&#160;&#160;As previously announced by the Company, Mr. Kenley was elected by the Board of Directors to serve as a Director of the Company effective as of October 18, 2010.&#160;&#160;Mr. Kenley is 60 years old.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>In connection with his appointment as President, Mr. Kenley has accepted an offer of employment ("Offer of Employment") containing the following terms and conditions: (i) Mr. Kenley will have annualized salary of $240,000, and (ii) Mr. Kenley has been granted options to purchase one million shares of common stock (&#8220;Options&#8221;) at a price per share of $0.25, of which 250,000 Options vest on October 28, 2011 and 20,833 Options will vest monthly thereafter.&#160;&#160;In addition, Mr. Kenley will be entitled to benefits customarily provided by the Company to its employees, including health insurance and reimbursement of expenses.&#160;&#160;This description of the Offer of Employment does not purport to be complete and is qualified in its entirety by the Offer of E
mployment attached hereto as Exhibit 10.1, which is incorporated herein by reference.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and Vice President of Electronic Drug Infusion. During this tenure at Travenol he helped to develop and manage the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.&#160;&#160;In 1991, Mr. Kenley founded Aksys Ltd. to develop and commercialize a daily home
 hemodialysis system which was launched in 2002 as the PHD system. In 2004, Mr. Kenley initiated the development of a second generation home hemodialysis system in partnership with DEKA Research &amp; Development Corporation in Manchester, New Hampshire. In 2007, the assets of Aksys Ltd. were acquired by DEKA where Mr. Kenley is now employed and continues work on the second generation home hemodialysis system along with several other new dialysis products.&#160;&#160;Mr. Kenley is the author of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at the Kellogg School of Management and other business schools in the area of entrepreneurship.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>There are no family relationships between Mr. Kenley and any executive officer or Director of the Company.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On October 28, 2010, the Company issued a press release announcing the appointment of Mr. Kenley to the office of President. The full text of the press release is set forth in Exhibit 99 attached hereto.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ITEM 9.01</font></div>
</td>
<td align="left" colspan="2" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FINANCIAL STATEMENTS AND EXHIBITS.</font></div>
</td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(d) EXHIBITS</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Offer of Employment for Mr. Rodney Kenley dated October 27, 2010</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock Option Agreement with Mr. Rodney Kenley dated October 28, 2010</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release dated September 28, 2010</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
&#160;</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;AETHLON MEDICAL, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:&#160;<font style="TEXT-DECORATION: underline"><font style="DISPLAY: inline">/s/ James A. Joyce</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A. Joyce</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dated: November 1, 2010</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div><br>
&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT INDEX</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consulting Agreement with Rod Henley dated September 15, 2010</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Press Release dated September 28, 2010</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">5</div>

<div>
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex1001.htm
<DESCRIPTION>OFFER OF EMPLOYMENT
<TEXT>
<html>
<head>
    <title>aethlon_8k-ex1001.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div>Exhibit 10.1</div>

<div>&#160;</div>

<div>&#160;</div>



<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="aethonlogo.jpg" alt=""></font></td>
<td width="50%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> </font>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8910 University Center Lane, Suite 660</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">San Diego, CA 92122</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">858-459-7800</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">858-272-2738 (fax)</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div><br>
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">October 25, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Rodney S. Kenley</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1402 Pearson Road</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Libertyville, Illinois 60048</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dear Mr. Kenley:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is my pleasure to extend the following offer of employment to you on behalf of Aethlon Medical, Inc. (&#8220;Aethlon&#8221; or the &#8220;Company&#8221;).&#160;&#160;This offer is contingent upon freeing yourself from any conflicts with DEKA Research and upon final approval by the Aethlon Medical Board of Directors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title</font>:&#160;&#160;President</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Base Salary:</font> Will be paid in semi-monthly installments of $10,000, which is equivalent to $240,000 on an annual basis, and subject to deductions for taxes and other withholdings as required by law or the policies of the company.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Confidentiality Agreement:</font> Our standard confidentiality agreement must be signed prior to start.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Benefits:</font> The current, standard company health, life, and dental insurance coverage are generally supplied per company policy.&#160;&#160;Employee contribution to payment for benefit plans is determined annually.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Stock Options:</font> Options to purchase one million shares of common stock (&#8220;Options&#8221;) at a $0.25 strike price.&#160;&#160;250,000 Options vest one year from the date this letter is signed bilaterally and 20,833 Options vest monthly thereafter.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Vacation and Personal Emergency Time Off:</font> Vacation is accrued at 3.33 hours per pay period, which is equivalent to two weeks on an annual basis. Personal emergency days are generally accrued per company policy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Start Date:</font> Upon Approval by the Aethlon Medical Board of Directors</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Car/Phone/Travel Expenses:</font> Normal and reasonable expenses will be reimbursed on a monthly basis per company policy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Your employment with Aethlon is at-will and either party can terminate the relationship at any time with or without cause and with or without notice.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">You acknowledge that this offer letter represents the entire agreement between you and Aethlon and that no verbal or written agreements, promises or representations that are not specifically stated in this offer, are or will be binding upon Aethlon.</font></div>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If you are in agreement with the above outline, please sign below. This offer is in effect for five business days.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Signatures:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ James A. Joyce</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">James A. Joyce</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aethlon Medical, Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: October 25, 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Rodney S. Kenley</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rodney S. Kenley</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: October 27, 2010</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>aethlon_8k-ex1002.htm
<DESCRIPTION>STOCK OPTION AGREEMENT
<TEXT>
<html>
<head>
    <title>aethlon_8k-ex1002.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: center">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibit 10.2</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: center">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AETHLON MEDICAL, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTICE OF GRANT OF STOCK OPTION</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notice is hereby given of the following grant of an option to purchase shares of the Common Stock of Aethlon Medical, Inc., a Nevada corporation (the &#8220;Company&#8221;):</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;&#160; </div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%">

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Optionee:</font></font></font></div>
</td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rodney S. Kenley</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%">

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Grant Date:</font></font></font></div>
</td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">October 27, 2010</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>:</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.25 per share</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%">

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Number of Option Shares</font>:</font></font></div>
</td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,000,000</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%">

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Expiration Date</font>:</font></font></div>
</td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">October 27, 2020</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Type of Option</font>:</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nonqualified Stock Option</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="25%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Vesting Schedule:</font></font></font></div>
</td>
<td width="25%">

<div align="left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">250,000 shall vest on October 27, 2011, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,833 shall vest on a monthly basis&#160;thereafter for thirty five months and 20,835 shall vest on October 27, 2014.</font></font></div>
</td>
<td width="25%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div>&#160;&#160;&#160;&#160;&#160; </div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Optionee agrees to be bound by the terms of the Stock Option Agreement attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">No Employment or Service Contract</font>.&#160;&#160;Nothing in this Notice or in the attached Stock Option Agreement shall confer upon Optionee any right to continue in service in any capacity, including as an employee, for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to terminate Optionee&#8217;s service and/or employment at any time for any reason, with or without cause.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Definitions</font>.&#160;&#160;All capitalized terms in this Notice shall have the meaning assigned to them in this Notice or the Company&#8217;s 2010 Stock Incentive Plan.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;&#160; </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">

<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Aethlon Medical, Inc.</font></font></font></font></div>
</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dated as of:&#160;&#160;October 27, 2010</font></font></div>
</div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;James A. Joyce</font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: James A. Joyce</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Chairman and Chief Executive Officer</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">OPTIONEE</font></font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Rodney S. Kenley</font></td>
<td valign="top" width="11%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: Rodney S. Kenley</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%">&#160;</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Address:</font></td>
<td valign="top" width="32%">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1402 Pearson Road</font></div>

<div>Libertyville, IL 60048</div>
</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ATTACHMENTS</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit A - Stock Option Agreement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT A</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AETHLON MEDICAL, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">STOCK OPTION AGREEMENT</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">RECITALS</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Board of Directors of Aethlon Medical, Inc. (the &#8220;Company&#8221;), in a telephonic Board Meeting held October 27, 2010, has deemed it fair and in the best interest of the Company and its stockholders that the Company issue to Rodney S. Kenley (the &#8220;Optionee&#8221;) an option to acquire an aggregate of 1,000,000 shares of restricted Common Stock of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All capitalized terms in this Agreement not defined herein shall have the meaning assigned to them in the attached Appendix or in the Company&#8217;s 2010 Stock Incentive Plan (the &#8220;Plan&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">AGREEMENT</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOW, THEREFORE, </font>it is hereby agreed as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Grant of Option</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;The Company hereby grants to the Optionee, as of the Grant Date, an option to purchase up to the number of Option Shares specified in the Grant Notice.&#160;&#160;The Option Shares shall be purchasable from time to time during the option term specified in Paragraph 2 at the Exercise Price. Except as otherwise provided herein, this option shall be subject to the terms and conditions of the Plan.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option Term</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>This option shall expire at the close of business on the Expiration Date, unless sooner terminated in accordance with Paragraph 5.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Limited Transferability</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">. </font>During Optionee&#8217;s lifetime, this option shall be exercisable only by Optionee and shall not be assignable or transferable other than by will or by the laws of descent and distribution following Optionee&#8217;s death.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Dates of Exercise</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;This option shall become exercisable for the Option Shares as specified in the Vesting Schedule.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Cessation of Service</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font> The exercise of this option shall be subject to the provisions of Section 6.6 of the Plan with respect to exercise after Termination of the Optionee; provided that, for the avoidance of doubt, no previously unexercisable portion of this option shall become exercisable after such Termination.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Stockholder Rights</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">. </font>The holder of this option shall not have any rights as a stockholder of the Company with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price and become a holder of record of the purchased shares.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Manner of Exercising Option</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable, the Optionee (or any other person or persons exercising the option) must take the following actions:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Execute and deliver to the Company a written notice setting forth the number of Option Shares for which the option is exercised;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(ii)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Pay the aggregate Exercise Price for the purchased shares in cash or in one or more of the following forms:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(A)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">by cancellation of indebtedness of the Company to the Optionee;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(B)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;if approved by the Board, by surrender of shares that either: (1) have been owned by the Optionee for more than one year and have been paid for within the meaning of Rule 144 promulgated under the Securities Act (and, if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares); or (2) were obtained by the Optionee in the public market;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(C)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">if approved by the Board, by waiver of compensation due or accrued to the Optionee for services rendered;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(D)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;with respect only to purchases upon exercise of an option, and provided that a public market for the Company&#8217;s stock exists:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(1)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;through a &#8220;same day sale&#8221; commitment from the Optionee and a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#8220;FINRA Dealer&#8221;) whereby the Optionee irrevocably elects to exercise the option and to sell a portion of the shares so purchased to pay for the Exercise Price, and whereby the FINRA Dealer irrevocably commits upon receipt of such shares to forward the Exercise Price directly to the Company; or</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 144pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;through a &#8220;margin&#8221; commitment from the Optionee and an FINRA Dealer whereby the Optionee irrevocably elects to exercise the option and to pledge the Shares so purchased to the FINRA Dealer in a margin account as security for a loan from the FINRA Dealer in the amount of the Exercise Price, and whereby the FINRA Dealer irrevocably commits upon receipt of such Shares to forward the Exercise Price directly to the Company; or</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 108pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(E)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;by any combination of the foregoing.&#160;&#160;Except to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must accompany the written notice delivered to the Company in connection with the option exercise;</font></div>



<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>



<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iii)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(iv)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Execute and deliver to the Company such written representations as may be requested by the Company in order for it to comply with the applicable requirements of federal and state securities laws; and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(v)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Make appropriate arrangements with the Company for the satisfaction of all federal, state and local income and employment tax withholding requirements applicable to the option exercise.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;As soon as practical after the Exercise Date, the Company shall issue to or on behalf of the Optionee (or any other person or persons exercising this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;In no event may this option be exercised for any fractional shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Compliance with Laws and Regulations</font>.</font></div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and the Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or the OTC Bulletin Board, if applicable) on which the Common Stock may be listed for trading (or quoted) at the time of such exercise and issuance.</font></div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained.&#160;&#160;The Company, however, shall use its best efforts to obtain all such approvals.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Successors and Assigns</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>Except to the extent otherwise provided in Paragraph 3, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and the Optionee, the Optionee&#8217;s assigns and the legal representatives, heirs and legatees of the Optionee&#8217;s estate.</font></div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Notices</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company at its principal corporate offices.&#160;&#160;Any notice required to be given or delivered to the Optionee shall be in writing and addressed to the Optionee at the address indicated below the Optionee&#8217;s signature line on the Grant Notice.&#160;&#160;All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properl
y addressed to the party to be notified.</font></div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify">&#160;</div>

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Governing Law</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font>&#160;&#160;The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of California without resort to the conflict-of-laws rules thereof.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF</font>, the undersigned have duly executed this Agreement as of October 27, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;&#160; </div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="38%">

<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Aethlon Medical, Inc.<font style="FONT-WEIGHT: normal">, a Nevada corporation</font></font></font></font></font></div>
</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="49%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: #ffffff solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;James A. Joyce</font></td>
<td valign="top" width="11%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James A. Joyce</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chairman and Chief Executive Officer</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Optionee</font></font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></td>
<td valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/ Rodney S. Kenley</font></td>
<td valign="top" width="11%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Rodney S. Kenley</font></td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="32%">&#160;</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="7%">&#160;</td>
<td valign="top" width="32%">
<div>&#160;</div>
</td>
<td valign="top" width="11%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div id="PGBRK" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">APPENDIX A</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following definitions shall be in effect under the Agreement:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;&#160; </div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.</font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Agreement</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>shall mean this Stock Option Agreement.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Common Stock</font> shall mean the Company&#8217;s common stock.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise Date</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>shall mean the date on which the option shall have been exercised in accordance with Paragraph 7 of the Agreement.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">4.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exercise Price</font> shall mean the exercise price payable per Option Share as specified in the Grant Notice.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Expiration Date</font> shall mean the date on which the option expires as specified<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>in the Grant Notice.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%">&#160;</td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Grant Date</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>shall mean the date of grant of the option as specified in the Grant Notice.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Grant Notice</font> shall mean the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the option evidenced hereby.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Option Shares</font> shall mean the number of shares of Common Stock subject to the option.</font></font></div>
</td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="90%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td width="5%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.</font></font></td>
<td width="90%">

<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Vesting Schedule</font> shall mean the vesting schedule specified in the Grant Notice pursuant to which the Option Shares shall become exercisable.</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div>&#160;</div>

<div style="TEXT-ALIGN: center">5</div>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>aethlon_8k-ex9901.htm</title>
    <!-- Licensed to: Publicease -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
<hr style="COLOR: black" align="center" noshade size="1" width="100%">
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><img src="aethonlogo.jpg" alt=""></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aethlon Medical Names Rod Kenley President</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">San Diego, CA. &#8211; October 28, 2010 &#8211; Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has named Rod Kenley to be President of Aethlon Medical.&#160;&#160;Aethlon Chairman and CEO, Jim Joyce previously also held the title of President.&#160;&#160;Mr. Kenley recently joined Aethlon&#8217;s Board of Directors and will retain his Board seat as an inside director.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;We are extremely pleased to have Rod become a full-time member of our team,&#8221; stated Jim Joyce.&#160;&#160;&#8220;As referenced when he joined our board, Rod has been instrumental in&#160;&#160;&#160;commercializing some of the most important advances in the dialysis industry. He is among the best in industry talent, whose full focus towards our endeavors will immediately impact our business and improve our efficiency in advancing established and future opportunities.&#8221;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and VP of Electronic Drug Infusion.&#160;&#160;During this tenure he conceived of and managed the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley founded Aksys Ltd. in January 1991 to develop and commercialize his concept of a daily home hemodialysis system which was commercially launched in 2002 as the PHD system.&#160;&#160;In 2004, Mr. Kenley initiated the development of a second-generation home hemodialysis system in partnership with DEKA Research &amp; Development Corporation in Manchester, New Hampshire.&#160;&#160;In 2007, the assets of Aksys Ltd. were acquired by DEKA, where Mr. Kenley was employed prior to joining Aethlon.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at Kellogg and other business schools in the area of entrepreneurship.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from the Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg Graduate School of Management, also at Northwestern University.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Aethlon Medical</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Hemopurifier&#174; is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier&#174; captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier&#174; can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human studies have documented the ability of our Hemopurifier&#174; to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.&#160;&#160;However, our initial clinical and commercialization focus is to establish our Hemopurifier&#174; as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier&#174; in India as we advance our clinical strategies in the United States and the European Union.&#160;&#160;<font style="DISPLAY: inline; FONT-STYLE: italic">In vitro</font> studies conducted by government and non-government research institutes have also verified that our Hemopurifier&#174; has broad-spectrum capabilities ag
ainst bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a therapeutic device, the Hemopurifier&#174; provides us with a pipeline into four significant market opportunities:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160; &#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Cancer</font>: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160; &#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Hepatitis-C Virus (HCV):</font> As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160; &#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Human Immunodeficiency Virus (HIV):</font>&#160;&#160;Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160; &#160;&#160;</font></div>
</td>
<td>
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Bioterror and Pandemic Threats:</font>&#160;&#160;Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Hemopurifier&#174; is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier&#174; is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In design, our Hemopurifier&#174; is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier&#174; via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier&#1
74; in as little as 15 minutes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contacts:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">James A. Joyce</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chairman, CEO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">858.459.7800 x301</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jj@aethlonmedical.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">John P. Salvador</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director, Communications &amp; Investor Relations</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">858.459.7800 x307</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jps@aethlonmedical.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Jon Cunningham</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RedChip Companies, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">800.733.2447 x107</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">jon@redchip.com</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><br>
&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="1" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>aethonlogo.jpg
<TEXT>
begin 644 aethonlogo.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!I`1H#`2(``A$!`Q$!_\0`
M'P```@$#!0$```````````````H)!P@+`0(#!`8%_\0`2Q````8!`P,"`P4$
M!@<##0```0(#!`4&!P`($0D2(1,Q"A1!%2(R46$6&(&Q%W&1P='P(R0Z=:&X
M\5ARMQDH,S0V0D-2@HB8LN'_Q``=`0$```<!`0```````````````0,%!@<(
M"00"_\0`.1$``@(!!`$"!0(#!@4%`````0(#!`4`!A$2(0<3"!0B,4$582-1
M<18R@9&A\"1"8K'!,T-RT?'_V@`,`P$``A$#$0`_`'^-&C1IIHT:-&FFC1HT
M:::-&C1IIHT:-&FFC1HT:::-&C1IIHT:-&FFC1HT:::-&C1IIHT:-&FFC1HT
M:::-&NL8X%$H&4[1.8"D`5"AW&,(`4H<E\B(CP`<<\B`?KJ$;?[UN<$;1Y2:
MQ5B!FVW';@(U=[&S%?A)]M'XSQE*H@JT5;9&OC5I()K6"*D``7F/*V1W8R*-
MW4?87],$47@W'M/:&Z-\Y:#!;2P=[.Y68CFK102"NA=4::W.66"M"A=0\TTB
M1AF52W9U!HF>W'A=L4),IG\C5QE%!XGLR`&5RI98H(E[2S2N`>L<:,Y`)("A
MB)N%E@*IZ?(B)4RJ'*4`$"$,8Y2G.(_@*(D/P83%#[AO(@`@%H.7=_>R?"#M
M[%Y6W28/I\]%NE6LC5W.0J]*VY@Z0()E&SRI5YU+V-LXXX[45HLBIA^X4ACC
MVZ1(W,=0O>9N[>OAS/G.U)5)X*Y28HQE(2>-,2-F;A4BZ<<ZJM=E2N[DDS$I
M"(O<CR]MDTU2**-EVJ:H)%LI9QK"/2!"/9MF"`!P"+)%-HEQX\=C<J91`1*`
MF`0X,8`,8!$`$-W]H?`G>E2*SOS>4=*1UC:7$[9JI8GB!X9Z[YJX$CCE3P&>
M&A;C#AD!8<D:Z9WXDD5F3:^WC(H8@7,W+)!V4$=95HU',O5E'*JUJNQ5E8^/
MI+Z3KKJ=+)DY7:*[FIA51LJ*:JD=MRW22K$Y@X\MI*-P>[8O$_(=JS1RJB<>
M>U0>!XK!0.K3TX,DK-6]>W>8MBG#PH"@UR(M/8@<F#@1#U&V6*]2UT.>T0#Y
M@B0F,`E#[P<!CV>T/U#^H1#Q^7@0\#]0]A`1`>0$=;!21$!`44!*/;P04$1(
M02")BF3)Z?:D?DP\J)`0Y^>#F,`!K(=OX%/3-ZYCH[LWY6L$#^-;LX#(P*W@
M'_A3A*C/P!R";<9YX!'`Y-JQ_$9N\R@SX7;;0\@LL2YE93^P+9<QC^?)##G\
M:RDU=LM?MD''62L3L/9J[,-4GD5.UV2CIR&D6JQ1.DYCY2*<NV+ULH4/]$LT
M<K)JCP"9CB)>?1)"4R9!+^$0Y#P)1XY'W*/DH_F4?(#X'R`ZQ?.(<N9;V]6$
MMJP'E'(&&)TRX.';O&UG?5EG,'(HBL1&SP:#D*U;(T%F[=16(M$#88UP"":9
MV``!5$V--F'Q#]G8R$-C[?14T)&$5^78-]PF)H)T26:.#JH(H*9#Q1%DDADT
M%RK'6D;)CLL:HT.V*V:8\<E<*/$=>/4#X-/43:<-B]M"VGJ!BH5>405*<>,W
M"(D0NY&($DU>T\2*Y>.E>GLNH#I5Z]A'E3:WQ`[7S$\%//UYMLVIR(TLR2&W
MB#*Q"K&T\:)+7,A/*R3U8X$`823J2H9M;1JG]"R-2<F5"#R!CVZ5F_46UL_M
M.KW&GSD?8:[/QO<=,7<7+Q2CB.=%(JBN@X*BN86SM%PU4*55!0I?=IB(B`\F
M\EX$!$.`$!X]N.>1^H_7GV#CC6H#]XYYJ\L;Q35Y&AGBD!6:"=#UDAG@/$L$
MD3!E<2*O##CR"#K/:,DD231R1R1R*&22*1)(W5@"C(Z,58,K!@5)!!'!_ERZ
M-&C4=1T:-&C331HT:---&C1HTTT:-&C331HT:---&C1HTTT:-&C331HT:---
M&C1HTTT:-&C331HT:---;%!,!!$G'=XXY`1#\0`/@..?'/'GWUP^JIW`42@`
MB8W/`"(@0/!1_$`@81Y^@A^G'G7,H8"$$PE$P`)>0#WX$P`(_J`<\B'N(`(`
M`CXU#'UGM^<ALWVYLJYC.6&,W#Y_/,4K'#U`P#(T.JL4D5,A92(0J9TTG=?8
MO(N`JJJRI12N-HA),&[QA#S#<;AVCM7-;YW3A-H[?A6;+9V_!CZO<E8(#/[C
M37+C<?14I5X);,T@Y,<<;MU;P#2<_G*&VL+D<]DW*4L76DGE`Z]YG;JD$"=B
M.9)9>(XP2%#N"QXYU'1UC>K[8&,W<=F^TZS.H5S"JK5K/6=:V^*C*,94AA2L
M6)\8RS<PK1DLQ1,>*O-W9&3DH)ZX<UVMNV%@CI.08*R-FJ39%-%$.TB10*4.
M1,8P^3*&54,(JJ&55$7"G<IPHY,HY6!1PJ=4=K5HFS03;HB/I)%$I>\3G45_
M]&;U7"BBBIE'*BPNW+A?[IG#AZL<Y2B4H:Y5ETVY`46.5,HF`@"82%`5#@`I
M)@8YR%]98!**"`"99?N`B*:A^2Z[6^E7I=MKTBVI6V[AE@]XH9\WN"=(J5_+
MW%\M8MVO=+Q5D3L5K^^M:%`O()0R'G;O/=^6WSG)\KE69HF(&.QH_B5L?$``
M*]>$J0\K'EFEZ-.Q[GL%)&N4`XY\\\_Y_EP'\-:ZJVEMXW)KID70VP[GG""Q
M$U45V^W'-3E%5)5,JJ:B:[6CKH*IG(<IB*I*G25*)5$5%$C%.;D_=SW,_3:W
MNE'_`.VO.(?GY\T(`_X_75\IG]O]1[>:PY3SU:/)4GC/G@E729D8<\_4&()Y
M/)^^J*N*RI4%<7E7!`(;]/O2=@1X(<PL6''`!Y(`X`\`#5(-&JO_`+N>YG_L
MM;I?_P`;,W!S^@<T0`Y$?`!SY'QJE\[#6"JS;RLVZM6:FV:-!,9&LW*N3E2L
ML?ZR95$1?5^PQ\;+M`5*<IDQ69E]9(%%$`5!,X!Z(,OB+<GR]7*XNS896=:E
M?(TIKDB)QV:*G'.UJ51SQS'$W)!4<L"-29Z=RJO>U2NUHS)#%[EFI8@3W)W*
M0J7EB11[CJR@D\`@]B/'/SNW^KZ_3\^?UY`//@`UH)`$#%,!3$,4Y#%,!1*8
MBA!3.4Q3$.02F((E$!*("`CX]@#>'D`T:]<BGR57MW;M(K@.CGJ1]<3\Q.//
M/#(0&`8`,`1YOY'^7G@_;^A'V8?L01SYU(=T\^I%EKI_Y"358K2UZV\6J9.[
MRIA-1T1=$"/'#09;(.-1D72)('(,8W%5PNV2<H0EV*K]DV9,L@XA+)7W[,1Y
M5HV<*!3<M8NL4=;\<9`KC2R56S1IE`1D6#P$^TAT%0(X9/F:Y73"7C'R+60B
M)-FXC7R";YN[;M<8&(>_Z_G[!X$`'^7\0`?IJ>?H/[['>!,[([2<@RY2X9W&
MV`"4%1XX52:T#/#QNI\HWCS*.?28PN7?EF]=/'(IJ'&^)5)9N<KN<L3^2TC^
M*ST#H;@PESU,VQ4%?=.!JO-N*G7A"IG<,.'DM`Q\-9RN,C7YB69QW:FAH@2M
M!%SL)Z*>IUK#9.OM#-2B3!9!TAQ5J1OKQ^0GDXCKNQX"4YG(10>52:16Y53)
MR['HUUT%#"0@&3,4W`]_(EX*8!'N*'!C<%`0'L#GP3@/<!#78US!Y!^QY_/(
M\C_/[:W-_)'Y!(/]1_(_8C]QR#^#HUH)@`>!'_@.N-0XD[...!-P/)1,(@`=
MP@7@2ASV@81Y'P`"(`;@0%63<G\5%@7%VY#+VT/;OLBWD;M]P."\I9$Q/?H&
MD5:NP]<=S6,+,ZH]HDZ:O69;*=^FX="Y-#PY'4KCBNI&35;.D5G'S+-)T\?G
M_OQ_X.G('WYX_8@<?N>?QII_N`?8>?X#_AK03E`0`1X$1```0'R(\\?3]!\^
MVDY+W\4MNUP?#O;SN5Z`^]_`F*6"OHNLBWJ:R77(=J=5RFDS3>N[[M0H-;9J
MN$U!$4E+2)BN12:IBN53UR3I],3J\;0^K10[S=ML$I=XF5QC(Q,=D?%65ZPP
MJF3J22QK3I*E+RS:OV6YTZ4@;<A7I9U"2-8M\X5(&+EE-EB)5)2.3@Q(!*KS
MQ^"P']26(X`'W^WXXU`<D^!R.>./LW^HX_T^VI1O53YX[O/]0_SXX^FCU2=P
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M/,_LCCAB>K`EB#U"?_,'_'_#_K]->`R-ES%.':\\MN7,FX^Q75(YA)RLA9LD
M7*NT:OL8J$;@[F9-Y,VB2BXYM'Q+4Q74D]6<D;,6QBKN54DC`<;*MC'4YVO=
M0)A)H88GIVO7VO-?M*QXER2TBX:_Q\(#E-G^T<<A!SMAKUIK:CE1)NK,5>Q2
MY(9T[8,[*WA9%XC'FQSGQ(G67P'U9;+MCK>$,8Y5H)MJLMN8A;1(90_8H&MG
M7R7*X;80[RK&IMMM22C=J3%4JX>JOUFR8%EX_P"3%RFDLX):6<P6:VUE;>$W
M!BK^%RM%_;MX[)5I*UN%_!4NDG!ZNI[(P4K(A#HS*>=5S&9.AF*4.1QEZMD*
M-E>T%JJW:&1>>"`>S?4#X93P5/@CD:RMT?(,)9DTDXMZUDHV0:MGS"18.$G;
M%^R>()N6CQD\;G4;NVCILJDNW<MU%$5D5"*)G,0Q1%8OK-_$=*=(C=1CK;*7
M9P.X@]_P%3LXENRNXE3$`Q9[5DK*F/`K)ZY_0;DXKM-D;&B<L::";8@Y";,R
M&&1"/^:>VT[>?C"-B=ZM&#,&QVVK=9%SUWL&+<3-YF41PHG!1DS8Y"`II)-^
MX;Y017"&CW;LSM=R6-:G,R0`X,F9E?01@M^,V0,KU8-N+1)-995?8=AQLW31
M(*BJBI]S.Z$A"%(`<G.?R4A2AR902%#WXU2M5`?8?C63E+R!?O=W(&,')N.1
M#O$"C]T1#@0X$/8>!#DI1Y*&[D/U_L'_``TL/U(_BIMANPG*=WV^TFIY"W79
MVQM892IY$@L?JQE)QI0+=7GKB-L=)LN3K05VX?W""D6_R<FQHU)N</&/TI*$
MFIZ)L<._A21N8U^-[PB\M)8S.W3[R]C:M(O7+24D\:9MJ&6[6Q!NU<`8"T^X
M4/!;)1V63(W9+M'-N8E1;*.G8.%'+0L:Y:@>WXXX_?G_`,:><TMQU"OB!GNQ
M+J;8*Z<J6T1OEE7.9]OZ$?EPVX1:@_L^IG;(\CCHHN:&3"%T"0+67+'[1X3N
M3$\LB<J11CCF%9.;K:GNNP1O7P?2MQNVS(,;DK$5_;OU:_86+*3B7C9Y$/3Q
M4W`V"#FV[&:@+#"2S=VRDHF58-'21BI+)IJ,UFKQX@M\0/\`[3QT^O\`>'3Y
M_P"9RP::'Q_F/]2!K(XI>IP8#B`\',!.![A$A?`"8W:3DP\<F#M#M-R7N4``
M4-RB/'^>?Y:VE]A_[Q__`-S:6!Z@OQ6O3VV3Y"LN%,=Q%[W@YBIS\\+:VN'E
M82$Q'5K,QDA93=5ELN6-TJ$S88U$P'.3'5-O\`WD$W,#+V.)G6<E'QS3R0".
M.2!]_MIG_D/U_L$/YAK7224?\99&4.QUIONLZ5NX_`-,LQE7,9/L,EM[19):
M(9^F22D:S5,D8CP1%6,[!5TQ350;W1NV+\XF+B0;&%$B[1>QOJ(;5>HUAIKF
M_:;E"(OM;14:1]PK;]):`R)C.R/"'!.KY%I+PQI.MRIE4'98]TH=Q7[*W:JR
MM1G)^"]*86:#G\\?X<_^=7Q:-1"=63K&X.Z0M/PQ=<X8PRQDV,S;:;?58%+$
MJ-+5<0SNG0\9*O5IO]L+=64?3>?:K=!H#!5WV@@]5<&2%)NF[LOW>_%`;!-H
M&&MO]WL$5D/)F9MQNWG$FXBN[;L;IU=];<6UK-.,H')M'99VN4E8F=7I"\E&
MS[%,K2&3M5N,Q<L;(VI;NKR<7,OFHZ9+T:1%@OC@*`-@30N_3?OM:J2HMUD9
MJ$W*P-BLJ\<Z6Y0?(5.9PK2V"Y561%W!/1MIVIG!$6HO2IK@[(U/TW>J)M,Z
MJ.'I;,6U>W2SM*I3"%<R3C&^1#>K9<Q5/OVQY"%9W>L-):=C#1UBC"+NJY:Z
MI/6>DSR\;/Q$59G=AJUNA*ZTU(<L43)&*41*8>.T0Y_$!@$O(`)1$HB``8O(
M=Q1$O(`.L>3U7-QSK<YOVSK:$'QGM(Q;.J8#Q>V]<KUFUK>,'!HVRR#,Z8?+
M*(VS)A;C9T7"20&<0SN";*JNB,4UCOM[A<FHX5P%G#,C@R9$,2X@R7DU8ZQ0
M.B1*A4N:M2AU2&X*=,I(H1.4P@!B@("/`ZQ@T6D[28-!?JG5?K(IN)%8YS+'
M6D'"8+OE55SB*BYE'"JA_55.<XB/`B/`ZWR^!K:L-K/;SWI8@22;#8ZKM_$2
ML`QKVL\ERSD94!Y"RO1Q45%9..RU[]L(5D*NNL?Q+9R6#$[=V]'(5BR60DR%
MZ(#@35\<JF*)F!#&.25V$J?],94JWG7>$X$+W&'P`#R(`(^2@81```.1'@IN
M``!$>.``1$`%C+H`;%(_)]_F=[>4:^E)TW%DL_IN!(N6C2NHVPY09B0EKR6@
M#L3)JH8V;HLZO67R:+UA^VDC.OV3F*GJ80IX&,+8;NVXG,>,L"XV036O.6;?
M&56$463.X9Q+4PGDK#9Y5%N"BQX"HUMA+66P"FDN<D/%NCII&4*0`R26W_!M
M$VXX6QA@S&[8S.EXKIT9484%@(+J2.Q("DI89<R90!U/V29,^L$\]-]]Y-2<
M@\4#U'*@#EWXQO5N7:.U(?3_``EKIGMY12279JX)EK[525X9E1^P,#9.=$HS
M2<,KU#=2,QOU.K`]!MDIN#<$FY<E54XO;;PBJM@<K/F)H.2A4CJZ5H9))0!_
M=D]COV!(-9DO5X$1$1$1#\8\`'W">"\<^P\@(_4>X1\^^\2J"'@>.!Y]^1'Z
M<?EQ_'^'MK<3C[W'U,(_\`#6_7*WH0`"S$#CZ3P`!^%Y`#<*.%!+=B`"6)))
MW;Y8GDCJ>?L..``?'[?;C_\`=?)D'B#)F_=.GZ#%LP:*O'KYVX39,V#1`AE7
M3MR^<$,U029MR*.'!U.2()E*=QZ:2A3BE%?^IULUZ_U\W#[-,1XW?T'='@<U
MXOVP+,,_/P[T-V==QB1\[O\`1X]FI!5N=J),A5=E*V:`QM)O;6D,.R;Y)E'L
M-(T9]64[J?BS^I9^Z'LB+M'QK/IML[;Y&4]3)P6+ADM)4O;/%E0:98E'C?UU
MW<>?*:DFQQ'"$D8H8Z?K<KE9W"RC*?IB/IXSS`6?LI[8LSXIW`8:L:M6R=A>
M\U_(-%FTR`NFTFZ\_2>I,Y%J($)*UR71*XB;-779SQ=B@7[^&ED',<[6;GK^
MU]Q9;9V?Q&Y<!;DH9?"Y&KDJ5F)F5A-5D601R$$,\$P7VIXB>)(F=/`=N:7F
M\/0W#BKV&RD2ST;]>6O*A5"\9D0*D\+,IZSP,!)`Q#!)0&*GC3'S=;UD04%!
MPV,4ZB"[9V@JV=LG2!A(Y9/FJQ"+M'K54IT'+9PFFLDLFJF<@&3.`<P#SY_P
M_NYU?IOBC,;9>C\%]2/;K%$C-MW4-K+[(IJ\1=Z\4P]N@BWK]MN)P[-/7;-F
MFN\2NC29EXJ4:-8^/LDC&WQ2N1#>K0<,]D+"P]O\>!]_/T\>P_3V]M=S_3[>
M^.]1-HX#>&)*K2S5$S/`>Q>ID8'$63QC,>.TN*L$5[+\=9'DCDCX1ASS<W'@
M<AM?/Y3;V24"SC)PJS+_`.E<J6![M&W`/)"20*QE5R6$C`#J`0==;!7?-%FD
MA%O7L7+13^.F(>6CE!2?1$S#R+24B)9H8#IG!W%231K)LC)*)K(OF;5PBHFJ
MB0Y=^MIN>/'OX_F`\B//(<``^P?F(B'&KPG1)*UI)462%JEH31N`R2P&O)[T
M;@@@K)%W1OSPQX\\'5%+O&.\9*RJ0T#`D%9P?X#`@@@K-T(X(^WWUDB]BVXP
MFZ[:1M[SZL=#[<R#08\]V;L4P*Q8Y)K"J]/R;&M@`5/391^0(.PLX[U#IJJM
M$6YS)E,H*9;O]+F?#>9&5GMK.:,6.7*RJF*-P4A+1;95T*Q&-=RA3X2=2:MD
M>>YLT<6MC<)<R1@[%9!\[<%`!,`%8SUPD]5]I)L3U*WQM.*-H:V'W'D8:43#
MS%CYY?FZ"$@`,?D[$+%P`'[=@%!`UTEV)FFW%L[;F9>3W9+F+@%A^..UNKVJ
M73Q]QS;@F^_/[:X5DS*`4"]G`&$3"<!,':)3%$.SV/W@82&`P@`%,)@Y$``:
M?T;'=`Q8ULD?CN@TZ@QMCN5GR);$J;6X"HL;->[J]4G;I>Y]"%9QR$Q;K7+K
M.9*TV21!:5EY,Y7D@Y7,8ZB=HG5,WM&Z<VP7<?O,0J`7Z5PU5Z^-9J*S@6T;
M,73(5[JF*J,$^LFNU=$J["X7B#E+2$<Y0ECUUE)IQ*GVB=L4R./3EZ?F_CXE
MUO<-V?4;WXYIB-IM;RN^ID+BVDF28IW.PP4'$2EF;8BQXX!IAG$4#7FTI5&)
M\ADQMD*8L\\PDHJ5A7<O%25B;X_U=FFW-\/7QZ3^T"DW%/(>YO%N<[4A$RT0
M?`.!YJOYTN]KECE?1TA1I]G57DK1J6HL1!VVF`RG9:M&(MP%LX,HX?1K&53+
M^#,?IK]5?<NL$8SK<8[V(9=DSUN-<3!XF&(EN3VQJ-HUK]O2DO-"W@V[A>-8
MJ34M)RQ&I>9"2>NU7+I=T7:'\/UTF=F*M:F\<;0Z5?\`(=;:Q":>5-P1E\Y7
M-Q.PK^+E&-Y8,;XM(X_H]V0EH1C)MI_&%&I"T4X^8)`H1C5^]064<^%=.XE.
MO#U#C.W"JZS[;?NY%5PN8RQC'=[S=OAUE3"H(B85%E5%E.1^^H=0QOO',(P*
MJX*.`4<%7!^Q1APP(_(*D@C\C7Q(7".8P#(%9HP?M[@'*?T^H#[<<??[ZO/V
MB[B-L.XCJ8Y5WM[^LG52!HD=)3]^PK`78DI,U]U*M+*UB\!P)8YK!O@>1>(\
M9I.)E'N813&9NJ\;;DT!DD9\CMGPG6(Z:)1$RN\''1@$_)1"/NY2"'CP(A6>
MSCGD0*'W0`0*83CR<RW'0CPCM]D=S>X?:?NQP9A'+-UJN/F\%6HS-^.*1?%H
M"[[<,AVRAY6C*C$W2%F2M).6-;64A.I1!2O5(ZJ(G5!=I&J+D:F3Z<?3M<!]
M[81LM4*'@O.UK!PD-QR/*8FHG!B_4!+R'(\<\@.MQ_B)G],:N_J>%W#0]0'K
M8':.T:VVZ6WLWMZK@ZN`&`I21?I4-[%9*S-";;6ULV`_66[',H3K'&=:_>DT
M&\+.V)\CA[^V$DOYW/3YB7+8[+6,G-DER4T5DV34RN/CCZ]%$,9B)CA*MV_B
M$%3C<?G/`]?ZS.`=SNQZ]P5OJ-VOFWRSY`F:,@Y80REXR/D:WX<SI4BM'C*&
M.@M<\=-V<_8$UDQ2=S]U=SZR:KPJ*BE)/CEN>.EWR)C"'[[X<F#@1X':6'MP
M`<>.`X``$.!+XXTY?$]/7I]0<K#3T'L;V?1,Y"24=,P,W%;:L,L9>'EXITB_
MB96+E&=+2>Q\A'O6S9Y'OVKA%=JZ106;JD6(F()H?'+<"7I=B'MV[W!'GCGS
M^Z27G]1$PA[?4>?SUA3U0]0<%OFGL:EA<9FZC;,VW'M>Q?S]W'7LCD:]/V?T
M[W9\?C\>K?*Q>]&O9'^AE(8L69LC;(VGD]L6-T37[F.ECW#F1FTH8NK+6IXV
MW-`(L@L0GEEF*6Y8TGX9N%;NJA4"*'S<?+KNJ'2W#E95PX7J5:67774.JLLL
MK",%%5555!,=1550YCJ*',8YSF,8PB(B.L9Q\:*JJGU3-OJR8J^N7I^XH.B=
M(1!4J_[QNZ?TE"'*`G(H502F*=/A4#`'IG3.)5"Y+['2I$\>T;O$Q1_8ZK<D
M%-0%`-]@,!],4^WO!7QQZ0E]3N$I.WO.4HXTOXS8YT^JOMT$@]I@V#8=\@`#
MY+N7W0&`0Y`?8Q2C_#CVY#6)-7ZOV']!IX#I"]*_"O3+VPXWJU>HM<5W*VZC
MPDUNGSG((,+#DS(^5;`SC9V\PI\@+1#";/B^MVL74;CZGI@TC(V'C6DU*MIB
M]S5LMT[\KKF[+\%[QNFYNM;9BID),V#"NW_,F:\,7@6");CC?)N.*!.7.&E*
M_/`47K.%FG5>90US@D#IM;-7EW;!X)5B,';*8`W@!X_Q]Q_7_(?35F'4=$1Z
M=^_,1_[&&Z/_`,$+SJ/'CG]^/]_YZB?`Y_?C_M_]C2COP/.1[')XCZAF(7+Y
MX>HT?(NW?)$)%G=*'CF=CRK5LIUFU2#5F81(@]DXS#E/0D')![G:,7')&`I&
M20:L\^('_P!IXZ?7^\.GS_S.6#5POP-/_JW4^^G^EV5^WZ-]U?Y\ZMZ^('_V
MGCI]?[PZ?/\`S.6#4-?)(/`_GU/^'8:9G^)HWN7W8QTK\E6G$\_8*?E7<%>J
MCM=HEWK;I9G*4E6_1]OM]WGV#]!9%W"2RN+<?7N$K]DB%6\W7['+PTU%NFSZ
M.:N$;)/A,NFYA3#^Q#'V_"PT"NS^YO<I(WJ8@;]9*^1>RXIQ%6+3:<85ZET!
MU)-UAK;:[(P-@N5IGZX6,D;M&7"(C[`\F8VOPA4/1?&3X^MMRZ2]+LM<B%Y*
M%Q'O-P_D+(#Q(O*<#4)/'N;L4-)9SR0Q2H+WK)U*@2F-P`.IMN'/<)0-?O\`
M#AY^KN>>C?LRF(]_7BRN*:',X"N\/#/&K@]7G\,VB7JL:VL9&Z:!8J=L%`0I
MF0G#-VD1TK'7!E*K+O4'B3Y9H#X''GQY_KX'_;_0?RU,?DG&-"S!0+7B[+5+
MJ^3,;W6&<U^W46[0D?9:Q:(9QSW,)N'EFSED]2,8J#@WK)*&3=H(NVPH+(I"
M&.0VX1[OH(?$_([5,8OK>]VK[E;YB["#&OS*[5T>7Q3NH:U5WBM19W*2TB=5
M3`.<9F,K9+P^52MTS4J%<P*#1.[R;)YDIE5VZB:A0.13SV`!>3AZOW3)EY(/
M@XF$HD#N`P\<E'[HB&-EZH9T-Z/Q:NWG$&)6JMM4Q=G#9CCJZ2-7D8NPI"WQ
M&I"9NS=+,3Q[I<C(<45-Y;8V[1CI5-_7Y^@VAG*-T'30S<K4>?V/^_\`?.I$
M/C>#`3;]L,`QS$[LRYE$!+Y`0"@U,G8("'LH)NP>>2`0YA.`AR&KW/A@NF%B
MK#.RS#&^W*],:7O=UN7K3&TPF1L@Q!;'9<-X.@F+RAX1H>*I2<*^/5X>5Q5!
MPE@D)N'+%24E$V"%I3H\A6:M63-['_C?A_\`-^V%B'L&8\S`/M_[U%J/T'\P
MY'GZ>_@>--+])Y,ANEITTCB0HG+L`V;@4P@`F*'[NV-QX`WN`")0$0`>!$`Y
M`=-07[?X#\?LOY_W_IJXG<3MKPINRQ;9<'[C<7TC+^);>Q79S50NT,WF&Z+I
M1J]:,[%`.G"1GU:M\(1ZJXKMN@74=9*[(]DI`RL9(HH.4\=W\)V2<P!UK=V>
MVR'L4A-TYIA/<+CV:!R=9@RL#[#6<J`SJEQ=PK9R=F$XT;LYQJR47,\-&,;;
M/M&BA2NU%3Y+W6-2^&[_`-HZWE_[@WQ?^/E8TU]:?*ZEYET^G-OH^6Y$_P"Z
M)N$3.()`J/RI\4VE-X;TA$H"(,S+&$.>"CY#D"^<<J4"`4`3!(`*4`)Z0B"8
M@!A`!`#<=@&`I>XOL`CSR//(Y-+=+C9SF7:]N+Q`R(HH]RK@7+F.&9$@`53.
M[OCZP5EJ"0"4P>KZ\FGZ?)3??[?NC[:QVNR;;';M[6X'$NWJ`^T8Y&ZJ#-Y%
MG6"9W#F@8GKIT%LA6M03I"FP*V*9G4JZ^>IH,G5VLM<B%E$W$P@0>B/P7[CP
M^W]C^J62R]R&E2P%[&9C)V)6X,-)L9D)HI"`>S^[-AY*4"*"S6[<"^%9W34W
MXA<3?R6Y]EUZ$$MFUEH9,90K1C@SV8[+S2A7/T((XIDDE9V550*>?)&F2?AZ
M-EXUNG6O?!>XHQ;#DQ"5H&!47R20_9V+X:41;7"^-BG,]6:.\@6>-2A&*BAF
M[@E:JWS$:"T-9P<.F>$@[4RAP`<<AP'/'`"(![B(^W'U']/&O+4VEUB@U:MT
M2G03*N4REUR%J52@(U,48Z$K==CFD5"P[!/U#G39QL>S;-6Y51,KV)CW',``
M8WK``"AP`<`'_7ZZTF]2-]93U(WMG=X90A&R=D_)5`.$Q^-@`BH4$'+`+!"I
MED*MUDM6;,G`[`G8G9FUZFS=M8O;U0AQ2@#6[''#7LC,?<NW9?`Y:6;ED)'9
M4(7P%`UKKPN3;[2<4X]N^5,E3[.IXZQC4;-D.^VR1%0(VKTRE0;^RV:Q2(MT
M5W?R,-#1CR0=`S16<BDW-Z2*H_=U[)41`_/<H`=I/!>./QC[<A^(WL/Z>W(^
M-*Y?$D;I(R7PDVZ<T!-JMIK<%!,+3G&4C'BB,K3\5L;$1:CQ*)FXMCED[M=Z
M\64<,EGK=)]6J5)P<TU7KUP773\>Q=EYWU%W3C]H;9KK8R^1CMSQ^\7BJP5*
M$)FNV[=@1NL$%=0`2P+2.\:Q*Y;Q[-R;CQ>U,1/F\O,8J4$U6N2@5I9)[4R0
MI'$C,@=E+]W^H<1J[#DJ1K'5=4??W=^I=O=S9NPMR#N%AKA-I5[%%)65<&)C
M["M1!6+QQ4#I'E9-HC+DATD;#=E(I1.%F<BSMNLD6QB6LL2/1CX-[#Q]>`\_
MJ/&O:7RE3E`M=EIUE;(-9RNRKZ,?)I"H9%11NX$I7;0RG8H9F\1])\P6.0GS
M+!VW<`4"JD$?%B'("'YZMZ_0MXRW9H7X&K7*=BQ4MUI"ONU[=2>2K;KS*I/2
M6O9AEA=3_P`T99>496-8@FCLP0V8'26">-)898V#)+&ZAE=&'@J0?!'@\<CD
M<'3/'P_F?ZCEMCN"Z/>:+,RK]&WCJ)Y4VDVF=6:-8[%F^W'$6B>J"#\S;UF<
M5FVLP4?3;`H#Q:8ECU2MT"IHMIN^/I-7WDO"3]3G9ZGV^&>URXU&PS]1N%=D
MD1;R$!;JM,/8&S0SXHE3;B\C9J.D&KH&@^@59(2I)(E5;H"K?3K?:,?6JO7B
MD62;IMTJ$["6JH7&LRCR#LU2M59E6<[7;+7)R,.A*0L[!S$>RDHJ4C'3208O
MFR+EHX273(<':]P^1:SOSVP[>.K3CR.C8Z5S,+7;]OJJ-?C@CH?&N\[&\!"-
M7%I^535>)Q]=S34F\%:X))5TZ+$1:E.+.3+NU6230:[H_!IZH_HFYK7IKE9P
M,;NZ9+.WWG<<5-S0P<355D=U6&'.UXV,G*MVOTZ2]@)6(UU^(+9GS^(AWE3B
M=K>#CCK95(AV,V+FE`-QHU'+24[+JS,..M627GD1J-6,ZVC^(O\`]7\M!?;Z
M^!X$!`0$H@`")3%'@2'`!#O(8`.0PB4X`8!``W(>0_N_/]?;GZ_PUT^[*L`D
M5NR*JS*PY'N1KQ,A4,`098^"H8`@L`W!YXT]8`$>00KQMR/L4#H_;_XE/J^W
M('W'(XTT%\,BIS:-]Z`&,)$HK:<L*0F-Z2*Z[O="0ZI2F4$@*KHHMP4$@`<W
M^B,<@%`HZ;(TM;\-=0%8K;]N0RFNF!#7_/453&*Q`$3KQ>+\>0K@IC'`A"BW
M2F+U.MB`!U"@Y2=!]U7O`&4M<8?B@NULAZ\>HDU602Q09'%XQI%XZM9PVWL/
MB+G7\]!;HSA">&*@%@IY4=`_1FM-4],MJ13HT<AK7Y@K`@F.QE\A8A<<@?3+
M#+'(A_*N".1P38?U-]FD/U"-BFXO9Q+V(M26S;36L=5[.L9Q\C`9!IECA,EX
MUF)A!IR]>UZ.O]*K;NR,&11=/J^E)M4A(*PJ$2CZ<&3^N[\/XCD;:1>>DYFW
M>_@BP7*4R12QP2SN5TB8"S/C-:W*6NG9APWC?-T:VJ]WB*['2RN-,@U2O6V,
M=@RG%(VGR$M8X^9R)FC6`]9.TO/TZ.JSU)=]NZF)QGECI&9:Z?.WVKX_O%YR
M3E+<HEFU63MSUJ>"KU#HF*']GP-A*KM;F[L\^G.S4=+_`+2`^HD)97#`8N2C
M68RD0?P[_2_W[[0>KCO'W$[E]MULQ#AO)."MQ58IEXG;#0I1A-6&W[H,*WBO
M12+6K6V<DT59.K5F>ED5G+)!H+>-5Y<E46:IKO)^?H`?V\?W#K:8HF[?`!P/
M(#R/(>!]O`:^77LC*!SV!4CMUY#?2>"`2"`200/O]N..0'8,&!'@\\'C\<?O
M^W@?GD_?\+@=1KI29SD-Q3'?STYK-&T_<.QEVMMN./U)EA6#6:[L&Z,4:XTB
M0F&CFGC)VJ+(,3D^DW(D95+W&"]E';]>6>2+"<\=`=5'K!46-5J>3>D??;_>
M8GTV#JU4JLY=@*Y(N"`0GVB5&K4C+U7E16*7U7+B$NS&.474-\JTCD"%:ILU
MBB8P&`Q@`!\<`8PE$/;D2CX$?J`<\`.M@H*%X!,2@'@!XX#\_/`IF_GR.LRX
M_P!9);6"Q.#WUL7:7J/'MVG%CL%D\]%FL7N&CC8`!7QARV#S6*:Y4K=3\O'<
MCE*>Y(&=D<*N.+'IXL.4OY/;6X\UM5LM,]O)4\9'C9J%F[(?XMLPY"O9,,\H
M"^X*_2-NH8*K%RT&6SK<;U>=Q^Y"@2VX#;!7=J>U"#C;W-VI%[7V+2XWB4&J
MOXFB4I^M>KU(9"C`:V29CK:K*Q&+J:192I#'/),[!^YC'4<GQ8?3)W4[_L)[
M7<L[4Z,[R[.;3Y+.H7;$%=0(OD6S4_+\9BIU^U-%AUG+9:V/*D]Q.1@^ID&D
M\N,VI:6"];BWYHYRFJW<8A_`@("(#SP81XXY#VX#GGCGSX\C[#K>0HE*!1X`
M0^A?;W^G/G6/=S9ZON/)I?J[;P>U:\5*M2@Q>WX[4=/BNI]VW8^<M7)I;MMV
M#RRF<KP@1$C50HNW!8F7#4GJ6,OD\W/)8:PU_*/`T_#(J>R/EX8(PB=05'3M
MRSDEN00@-L=ZI_Q.L>SVR;1I?IC6TE:B%\98:E]Q6;=D>ZJNVR+HL=(QU?=7
MF[V^?O6/L3GEZY2D#&<S<Q$1K25=1J;Z7^?EI!=1Y][XHGI/=0S?9U#\.9AV
ME;8;9F;&M0V>XRQ]8;1"6;'$&U8V^(SQN'LTC7T6MQNE;>O7S6#L];DU!9-U
MVR+:7;`NLFJ*I$7VS&`OTY_Z"(?VB''Z?75*IS.N&:SD"O8ELF6,9U[*UL9-
M)&KXPG<@5&(R)8V+]:4;L7<!2I"8;V6:;/7$),(-%XV,<I.5HJ221.=1@[*C
M08XI92RQ12S,J]V6&*25U3D`R,D:LPB3GM)*0(XT#/(RHK,*M)+%"H:62.)"
MZ1AI'5%,C_W$!8@=F\!1]R2`/)`-5O!@$.?J(>/T'^[CC5J.^FFV[)&RO>%C
M.@0#RTWG(6U3<-2J16H\[%-_8[C:<2VZ#K5?9K23^-8(O)J6?-F+,[YVS8`L
MKW/)!DB05!JC<L^87QS9*O3,BY7QEC^Y7APP:4BHW;(E,J]GN;R3E$(2/:U2
M`F9QI*SZ[V9<HQ+5*,:.3N9%5)D@51RH1(?)7'=YM8QU;)NB9$W)8`Q_=*V1
MF>P5&[9IQG5K5!A(Q\?,1H35;F[0RFH@9"%EHF99?:+%L#F+E8YZD)D'J!S^
MJMC<G=$)IXS)7/F(C8@6KC[EAY8`\<;3HD,+NT"R211-*%]M99$B+"1U4RI+
ME2,LLEF!"CQH_:6,".296>..0EN$D98V/1R&7CZ@.1RKE\)=TY=Z_3_;[^"[
MP\!63!ILM'VLFQW^T$[2)H+.6AH;A"VP6@5"T6([4T,-QK0N2R:;$#_:R!69
MG1T7A6M#^LYTQM^VX[KU[/=V6#=M=OR'M^Q>ZV7+W+)4;8,?,(B)+CS/DS9[
MEW1\U<(V?<!`0SI!\_!&*!5-#O7(FHU%)PHX+([KMM$/3(#)4MN`P?%8TM<J
MZ@:KD>3R_CEA0[//,0D#/86NVUU94H*9E&B<5)+.6$>^7=H),79E42"W6*3[
M>.=QF!,PR$M$XBS5B/*LM!M$I"7BL:Y.HUZDHR.<*`BVD)%C6)Z4=,&3A?N1
M1</$D4U5$SD(8Q@`!-C<DD3SMCKX@BDEBFG^3LF&"6&4P31V)1$4KO%,&BD6
M9D*2*4;A@0/D7*+R1Q)=I&60QB.-;=<RN95#Q*D8E[L65ED4`'Z"'XZ^=<6>
ML$XLW4X4RQMYS;5VESQ/EVISU`NM=>`4HNX>6;G1%_&/2"HO#V&%?^C,UBQ1
MYT)>MV*,BIV)692\8T<HH8U/8?\`$`?#NY,RM8>GC58O?GLRO<PC8W]"BZG(
M904EU2K/ZU5)"ZX"K<S4<XUK,,3#N8]S/6#`#J;IM@C&=<=7J:F(^O(UBNO[
MU_+6-;;:+E1ZG?*7:;OCI:.;9!IM<MM>F[5174PV7=0[6Y5Z-DG,O6',JBV<
M'CD9IFR.\(@JHW!0A#&"EUJWE;2:':7-%O6Y_;Q2KPQ<(M)"FVO-F-("T1SI
MR<4FS9_!R=F;2+1=RMPBW27;IJ+*B5,A1./;J7%1O3R20P4+\TT48FEABHVY
M)8X6CCE29XTA+K#)%+')#*5$<T;J\3.K`Z/=I0(C37:<2/,\$;RV8(UDFC;I
M)%&7D`D='/1U0L5?Z#PWC2=5]ZSGQ,FYAK&X;VQ=&;(^V*]W*MOH!_EC)6!L
MV(C!6!9DB8]HIEWS\RQ5@S&Q6QT'BT>QRHAD&,%59FU,J\=HE4=W^=`CH'6S
MIW6Z];T-Z-T@,H[XLLPS^+;IQDK)WAGAIC<ERV+(4J]O]E]=:]9GR"X^6;W2
MXQ[11I$(_M)7Z[9+/"6V>DG[.&0\I8[Q)7%+AE.\TS&M31=MV"]HR!;*]2ZV
MW?/.XK)FO.621C8U-T\4(8C5`7(J+]IS)E,4AA#JS>8,6UK'W]+EDR+0Z]B;
M[(AK!_2C.72L16.Q@+$LS;P,V%S>RJ5>^R9I:2C4XB1&0*SDCR+$C194[I(I
MI:06)$AD2K::.Q*(*\@JV/;L63U(JP2&,)-;X92:L;-8`928QV',Q[59'DC>
M>%9(8_>EC,B=XH//_$2ISVCK@@CWW`A[*R]^RD!6_P"*VV`[P]_F'MG=3VAX
M,L.;IZ@9,RI/W1E7INFP?[.1<Q4*Y'0CI^K<K+74.R1=L7:*1&JKHWJ,UR'%
M(RC<JS!O3EQY=,0]/78AB?)-?>5+(F,-FFU_'E^JLB9L>0K-TI6$:/6K37WQ
MV:[EH=Y#3D8^CG1FKEPV,NV.*"ZJ0E4-=E$S\3/QD;-P3]E-0<S&,YB&FXEX
MTD8F7BY!L@\CY&,D&:RS5^P?-'*+IF]:*K-73<Y545CD,43?3,L!2&4[3&`O
M/)2@`F'M$`$``!'D?/M[CQP`"(AJ3R/JY!4JSJX964JT;O&X8,`05>-U/(_Y
M3QXX.IPX(7J00P0H0>0P?PA!'(/;\:YM(F=#'I;[_P#;!UM=RFZ;<%MDN.,,
M&9`@=VB-:O\`+V+'DC%OG=YS!7+)5D18P%QEIQN$S#H.7+,RL9VG*B905`2!
M4R+NALJXU+D)/$9\@4<F5UJ\%N1QB>WUPN0UJF*ZC0;0E2QD@L9Z\#I%9J,R
M$;]G_,)*(_,>H0Q0^/CG.F&\Q(3#K$.5<:Y7:UUZVC;"ZQK?JE>D(&1>"<&K
M"94K$O)A%O%P25.DW?>@HH5)02E'L/VSVK64B:=JMD0)'%+)/\O-[$44Y(@E
MFF">U#'.0PA>5T65E81EBK`239K!@AL0"1FE18_>C]QW@7O,B1]N[O$G#.JJ
M652&(X()J?WF!OWF`"B7@>`$.."G^[P("/<`@`<?A$X#^%,3=I8MNGSTW:1L
MEO>[3)+(\'*3V>,RVN5HAXE-<Z>.\".9,UEI^,FY7;1N=H]:V";GG]A.R,=E
M)MVE3;JK.P@&SL\BE4R;0;\2S'HEQJMV3IEJF:-;U*A9(.S)U:Z5M1)&QU&Q
MGA7[TD):*\X5(WG*])&;R\4J/8]9HFX`:0PV\C:78[JSQM7]S>WN>R+(S*E>
MCZ##9KQI+7&0GDE%4E8)C7&-H7EGDT@=%0JT0V;+229B&3%IWE,4*UCLCNFC
MC-RX?$QY-,;E(,2-SUH*U@Q"I2M2Y&E)EU6%C4@KR0RV(I+!@0MW1F8/T:EW
M:^!GOX7)7Y:)NT+5N'#O/8@246K2FG:BIJ\BF6>01&%A&KL.A*`$!A<T'L']
M0:UT:ZZKCT@,)DE1*4#B8Q0`0`I>/O<<\\#R(AXYX*/@=6\2`.20`/S^/Y<_
MT\_?\#R?`U6^?M^Y51P">2Q"J/'\R0/V^Y\:I/G/,U&V\XLR'FS)<J,10\8T
M^4M]D<D,C\TLUCDSBUBHA%PNU0>3\_(&:0<!&&<I*2TQ(,HY!0JZZ8'QLN<<
MX7O<SF3).X#)RB2ETRS:'5JDF23M9['5R.2!&-J=-A'"I&JIX:CUAC%5R*44
M9(O%&S'[3D"HNY=8'#!WQ#^]0MMN-4V+T*6YB*,Y@,F[@#M3*E!Q<W;%"6Q7
MCE\)02!RW@H642RA-M4U%6RLC(XY53<%<QDDV36@X$1`W(#SY_/QQP`<B'/M
M[B/L/D//D>I7P<^E']F=H6_4+,0']<WG'\OAE>-?<H;83LJ3`\DI^K63':8#
MQ+4JU7(!+`Z4^O\`O5\YN"#:E%RV(P+@9)U8'YG,2MU(``X,6,B+(6_O"624
M`O\`B-#J'87+*P<9G2!:?Z_"C'5?(!4DRB=U%N.]&L3RJA3`*RT8NB:&?KJ$
M%8S.3@V:1/EH51PI$:)"<"/<;_X8@'!>!`PCW"(C[\<#["''CWTTE+0L79(>
M8K4\S+(P=DBW\!,,!4%,7<=+ME&3E%)7P*3GL6$S-<`,9%V5!8I#&3*72X.:
M,6S&'<EV7'\R8RXPSHAXB0`ARI3E=DB_.P4PWX*"9`>Q[AJ=RB!A,S?B[9K"
M#INNF7"?QD>E;X7=-;U(Q=5OT[=TR5=P)7@C1*NY8(446(8X0%6#.01+*)2@
M,EV*Z\I]R12^4/A_WJV6P$FTLA*'R>WE[T)&E#&YAQ.P4`.0[?+<B)O'TQ25
MD3GJ>M)_Z],%?#_[OZ9CG.&1-@FXI\Z1VC]2F`KV!+A("5`Y,3;@E9)9OMPS
MC%'<,W2[1S7;I*IUV553D:[!-SV*$NEN>/(W&T6S%?<$S^/NC^?N'/GS[=W(
M\?F`"&N5-+O.4ITS&]PX(!3&_"?[I0$Y1]0QA`"\\\&X$"G$.PVEE.>Y1MUK
MM-YJURG/%:J6(NRRU[5:1)H9(V'VE21%*'[*W!/C6P,T%:U!-6M1I/7L1/7F
MAD`>.6*9?;E213SV1HV8-X^QY!!TVUE7%=XP1E7)&$,F,"1V0<36^2I=I;H=
MH,G#ACZ3J*FHCN/\RI7K-`/HFR5IR\0:.'D#+1SDS?M5!52G;MT1HV5=&(=7
MT4S*`BF43K+&(03@W02("BQW#C@$FQ$DEA5<&21X+ZH*%O84S03J9].+#?4#
M4DC3FZ;:F>H[/^H8V.5A]LV>"*J[0V][H)E,CIW+OU[FR=L*M;K4[.S+.75_
M98N*C"U['C5=.[/HK;'GF[/=)$93N$*JK@3;'.05ZLSMTF7[,NF6&)PE\:X^
M:J&.)'Q(21:QV1+<B1-RT"$8UN'E2`VNK03]C]H^O>%RGHH?5;-B".?!4+,&
MX,<LBPI9W+5CA%3%Q1L>\,N;L&&2K"5`EK6WDBYBAE:/GSG/33,4O43^PE(A
MX\E.TN,LR=6(PMB9E>>?AO*4ZOOQ,5/*RU^BJW7RVKTU-N3_`&J[(=NF&)YB
M$=<XFE_MAD=F)0]=GDO)LM)9&OD4X7*LN+O[`LUH?UYJZ%8Q56$0T*BDV:E0
M:HWYZZB2:O)3=Q1#N#O'C@3F*)@4,(`4I?)^1*(``"'L`>-=O7'?,9:]G\SF
M,]DY?>R.:RE_*WI//$EJ_9DLS2`'R.[RDE>2%XZKPH`&_N,H5\7C:&,J@K5Q
MM.M0KAAPYBIQ)`KOY(+2!._;DENW9CV)T:-&C5.U[M&C1HTTT:-&C331HT:-
M--==4W:8!X$?!>>!#R`F$.``?J'//@?KY]O*E76%B+)&=1>W;A\>,7;_`"AL
MNZ>NU#=G2F#9(WI2;/&6_?([&_1<IV+-Q^Q4L?V2Q2LP40=)FC8]RR4;IDD#
M+I-JJ'`%`('X@`I_;P)1.(>!XX`0'^O^'OJUZY;0<%Y#S!?\X6ZNRLW=\G[8
M'NSZ[$7LDRA79C!S^T62V2$`:O-72#!M*O9:TRY5;(U(C,@Q<$9).DTD2:OW
MTUWI'L'<<V?LP264;$7\:U>,)[=RO?L4A9H6N2LHK7<9'>I6&KLDXALR".17
M*L+4WG@9=R89L9#TCE6W6N133=B(;%9'FHV45?#-6NQP3(C]D=D`<%"RE73=
M3=(W=[OBQMO3K$@M8,-XPZD/3;V2;=Y>,477AYQ!*?DLXYXGEDA351659VIW
M2XIH_04.@I'N/1<\O&C8#U@L6+IK)_6QZF\5!;)MK6^!]'UC;=)K4G=19*W5
MJO2Q)MQVY-TK+6).QX$SQZLP^.`1KAHUC((5&H"[6?+&8I-EYOJUTPMG]1PO
MA+`E?IUJ88\V^[AJ_NGQ\W'(=P7FPS)6Y^3L$+/V2QNI):8L[*/7E%(YM$S+
MIRR2AF,3%ID(UC6OI^?RYTIMJ.8<Y9*W&6-;/-:RMEPU5-?9W%.X_,F(FTR6
MGU&J4:!168X]MU>1!JA`4>N)K,C=[1T]8FD5T3NW"RALX0>M^Q5LSXNM!F:V
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MCQLLWB(6X*Q+M=)E/`1:3V\=,':WD+"&(-O%Q_ILL-&PCDAWEC'<U(;@\K+Y
M*A+V\4L:R<NMDAQ:%+M(FC%K.^4@T7$L8D(9!A]FF;@U*4W+A#I:[,,"Y889
MTK-`N5VS+7VZC*O9,S7F3*^<K-7$56B+,1@#90NEFBX:0;M4E6[&:1C23[!J
MZ?LV$BW9/G+=2T\9ZG[6Q^-P+MG-X7IMLC?_`+^`BQU2'%;MCW7->&&?-32[
MLLO4QYKV(ILE'D8<I=]H315K0D:&Q%5[^T<S?LYB(4L5#!G/[.,F5:_$][#M
MAJ\*WVBBI4Z\\U\/"RUS6FJKWD+2JM=7B,,+JZ9!QEFSXE:]X?5?1N1J]0L4
M2->F8$7+:>KI@QM;DY>T1;AGVKMY>JQ#^5M,4Z0,5RD[9I.45"'3,<L@W3+V
M'[`+'L'VV6E#;?MSS+(Y&Q'2KODC(-ZQ3CW)=ELV3YJ+)*7QI-SMDAIZ7%6I
MW=W/0;&`5=K)U@8\T<EZ;A)RLO(7CC:-@[$^8-QF<ZA!RH7O=2XJSS-!IZRR
MMAKUA"HQLA#1+9G79ARZA(1D,?*/&CYHP01;/4E!(L@)3&*:S,_1<V3LI.36
MQ^.X_"5+LDPM/6S#F%=TV:L>X;L\F[=).W[B2H<3<@CF;)_\NU9+Q=>4A8@D
M8T:Q36/;1Z)&^I6=]3=O;EQ%C!5\EN?:TB1[!LIGL=CZ-BUF#MKTWQ&T;.)O
MQU<]2O?I]+*XMKF(F-HU)EMSO9K+(8E2;CMG97%9&ME)*>(S$/N[F#8^]96)
MZ+YS<KYR.]1DL5[$3B6`1UK"=$9%@A6%B6G;5AO4ERBMNNWZ8JVG0&WK,6[/
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MW)8GR^:%^K-FMPU-Q8O*8Z5XZU&#$Y+%6:>$JQ9`0F>05;%/$2?+R,:@EO92
MPD'O2H37G9XD9+:/M9(*8@/[MV$`,($_"8,:5</2YXY[2@'@.1*7@>!`.=7(
M"8HD,0W@#\B`&`0X$Q2&`.?':<!X$`$0/W`;C\(\1:5CI98=P:;]M]OF2-R5
M8RG4Z?<X?$[C(VY_/V2L15BSSF.[)1:Q)6K$<SD-6HV6O5H\RV=MH12,(5JL
MP8KQQV+QJW=(W;;.MOK[;-MOQ3AJ=R9=\OVRI5UF>]Y0OUMMEPL5ZO\`)&-*
MW2P%D[K.V*>CH*1LCAXI7JPI+.6U<@4V$(F98&RRZ^$]QP[=L6<MD\+G+=_Y
MN]UCI9#"?I-Q8K$EZS/8*U\CEJ*QUS+7KJJ9!YI6F#")%A=Y,E8>3+QI1HW\
M.M.*M0B$MN'(QW(6FKM#&D*#V89B\G+R^XRA5564J696U&$^2;'^(I@%O22]
M='IK+]I_3`JW!\M2)`$5.`,8`(<Y>PXCV@`B!0X$=0M]/*2NNPG#^#.IG4#6
M2<VW7O*F3-N>_:BM"*R#.NU%KE^8@L09WA6B?^C:C0I2491LLF#`52F.]AHM
MVT-D.049-RK[3<,CNH9;S`BK"?.K'$XX2;RXVV?"MAC\TVZGOD35`ST]>!^5
MZZ5.,L5B1\H5-$%53&()Q\SAO8_MRP9MSGMIU.J+Y_@NU#D0EGJ%OLDY;%)M
MME->0=7)@YE95ZM+I-'JD@X%H1J\;JQO"0QZK=5,JH9BQOK'MNAM@8`XJ_?@
MR&`V#MG<E&:&/Y'*X3#'U!BW(L,KO)[=Z)-QX*]@K?M!J63Q\<@:%8U63'=C
MT^R=G.G*M9K5WJ9;=6;PMAI_KKY')_V0;&^]&J<O#+^DY>E<B\LU2RP202,)
M$5TS1DRUPG2ZZH%@Q'9G*-#R]UJ]RL+>LD4IT>23:8%R#;XBROK3%/8Q=$DW
M6[@Y_9B#=)MGHQ]@K%L=QYW*S&15%5E[">P;81CBJXG>XFVN[;W,?0VM/MV+
M<F-<3X]LET&4B6K1_7,E,<G'@GL[)6MUZ:,PA=$9LTNZ6<%=I/P*J03=_`O3
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MBOAX$!=XP#J5+O('`<\>`_,>.1[0`1#D`$1Y``$>1$!_(=6H;T-TE0V<;<,I
M[@[;\N]"D0BZ=2K*[LK1:]9%F"D846D,#=WKG5G9YPR1>K-4G"D7$$E)I9'Y
M*+=&+]3"NU?#6`,A[@LJ8YB[#'W'<W>8[(.6UI>WSUBCGUFCDI)!HX@XJ4>.
M8^LM"EE7QE6$&@S:K*J@HLF8R*8DCTZQO3]S_OPQYC9/"&3H".<X@E+):SX1
MN`J1-3RA8Y*+:Q\3-)W5FB_6@;C5X=.=@ZDWF8A>LN3725&3EX(G,B3&FR<9
MM;)[\V[CMS9Q,9LV?(8_]7R]RI-6*U@@DR-66*)[+UX99NM%+H?A8I?FC[1(
M6.[MRY'/4=KY2]AL2U[/I4N)CZ-2S#/VG[>TDD4CK&D\L<3&<5PA9G0Q@-QV
MTCS:[9:\BW&UY(R%+JV*_P!^LTW=+A/.#'%63L=@D7$C)N2D,<_H-BN5SH,6
MA3G0:,$FS5H!&23=(GQ@\``?EJH69</Y<VY7(V/L_P",[EA^X&5=),HR[1J<
M:SG2-%46Z[RH6$JJU7NT>FJNF<K^KS<BS5;B"KARP+P8:>%,!@`0$!`0YY#R
M`^`'P(<A]?'`CKNSBK>,M8_'RX*6A8P;58(L3/C'27'MCJ\:UZBTY8N(W@C@
MB2)&')^CZRS]F/-ZS%<AL3QY!9UOK*YN+:CEBLBR[%Y_?CF9I%D]QF+AF/GD
MCA2`-#``E,42@8#%,02F*4P"!RF*/'<`@4P<\D.'!B&`IR"4X%$+0MVFVEYG
MUA4I>K.8:.OE6=FBA7GW+EE$R50?`_>+-%W<=&23PKR'FU$G46F5,&_H2\R<
M_*H)D&[[D/\`(#Q_;[?0=`CP'Z_3GZC]`U2MZ;-P/J!MS);5W+7>WA\G&BS1
MPR&O8BGB<206JUJ,>['/"_!C!+1$\AXW!(-4VYN')[5S5+/X>:.&]0^8]HR1
M))&PM1)%(LH^EV3HHX0.!R2P\^=0N_\`DYLY``!^T>*!'P'_`+36+GG^-(]_
M`^!UN#IS9S*/<%CQ0';R81_:6PF`H$#O,)@&CF*)2E`1/R`E`H&$W@!U,ZV[
MWTM%P$:@[EK!./D(R$KL,S7E[#.23L_IM8^'A(\BTI)O'"GW"-F#1VY.`#Z+
M9<P`0TX^RSH2;E]P#Z&N&Y9)]MCPPL)'JT*^,R4SW;FGJD%%A%U-="0BJ`S?
MHIN2N)>_'0L;#EJF3';U%VJ^::?;X^'CX8?3G&OE-XY3<6(A]KW:]%MRU[&>
MNN0.E>G@8\6MJ61_N\HD$<*<R2?2/&;MM^KGK1NZ\,=M_'X6[(LHBGM?I"+4
MJ@\`RSNUL`1@@K_?!+^%+<<:B0^'/V:[TZ;ODLM2AJE3,Q[4,SXGM.%]]E83
MN5@84YGAJ[QCE*$L3J2D:JA"ER75[.A'R-!B&K9S=9J&6NU?A'%<K\W;;?7<
MC'M6VQXLVAX5I>`\/0KB,IM.C2@M*R2B#BTW&QN"H#.W2[2[5-I]MVNR.TOF
MY20%L@B!"(QK%I'PT?%L$/I[>]N.%]K^+XC#^"*1&8_HL*NY=%8,EW<I)3,L
M]\O[%:;!-*OYZSV244`BK^<G7[Z2<>DW0%T9DW;()UZ+^+@/H''/Y^>?[_\`
M^CKGSNG/8NU;R.*V5#F\-L::]!?@P^4RSY*6W;IQRUZF0OE!%2>[%!:M1Q?+
M5UCJQ3O&KRR$RMM/A,9D(8:U[<;XJ_N=*S5K-^A26K'!6E=)7JU0W:583(JL
MW9R7?LW5>3KD```.`#@`\``>P!^6C1HU:&KAT:-&C331HT:---&C1HTTT:-&
MC331P'Y!HX#\OU_C^>C1IIHX#WX\_GHX#\@T:---&C1HTTT<!^7Z?P_+1P'Y
M![<?P_+^K1HTTT:-&C331HT:---`@`^X`/\`7HX#\M&C331K3@/R#^S6NC33
M6G`?D']G^?S'6NC1IIKQEYI%.R+!.ZA?ZE5+U490I`E:O=*Y&6F`D?2/ZC?Y
MN'F6KV,<"DL4JA!<-5A(8H&3`A^#A%GD[H:]-K)3AV^;8*>XJDWBQUSOL-7N
MVT1B@<Y>PA&%50EGE(CVJ'<(MHYC5FL>E[%:F*!2A+RI^,/^Z/\`,-;%?P$_
MK'^_5>V_O'=^T9IIMK[GSNWWE8-(,/ELECXY^.GTVH:]Q(+2>>>DL13GSUY\
MZI>5V]@LZD:9K#XO*HA'M_/T8++1<D$^V\JLR<\>2O!(\$D>-+N/OAK-FCEV
MX<-MQ&].);KJ"9&,8W;;PJS9$'@H(MU93;+*2BA"]O=_KL@\6,8X@HL<H^*N
MX_\`A\.GM33-E;0AG+,:C8H`8<AY<=0B+OCNY%XRP["8G8J]_=P<A&B:9@(7
MD@AR`SB#^#^!?[M:D_"'\?YCJ[+WKYZTVZQAG]3-V>R%"?P<K;@L+Y']RU',
M)8U_Z5X\DGGSJW8_3'T^CE,R[.V\'5@JDXNJ1P0IX(Z>?)_/C]AR3JW?`NU#
M;AMEC%8W`&$,8XG3<-P:2+^FU1A'6&9:`HD<I+#;%D5K18U!,@D85IF8>*G4
M3(<QQ,1,Q+CDN13((B`CQR(@`@'=Y[N`,(F#SSX$1$/;D??7'KF)^$/X_P`Q
MUCJ>]=R<TF1R%VY?MW&,T]G(67N6I)&"EC):FYED)_)<DD^22=7?6IUJ,*5Z
FM>M4ACY5(*5=*E9!P#_#KQ_0GW_'[_SUNT:-&I6I^C1HT:::_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
